Bio Pharma Dive
JUNE 14, 2024
The Australia-based company had proposed raising $202 million via an initial stock sale, but withdrew its filing, citing its shares’ recent price appreciation on Australia’s stock exchange.
Pharmaceutical Technology
JUNE 14, 2024
If exercised, the option would allow Takeda to license the TKI olverembatinib outside China, Hong Kong, Macau, Taiwan and Russia.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
JUNE 14, 2024
The Japanese pharma paid $100 million to secure option rights to an Ascentage drug. Elsewhere, J.P. Morgan Private Capital closed its first fund and the FDA gave new COVID shot advice.
Pharmaceutical Technology
JUNE 14, 2024
AbbVie has made a licence agreement with FutureGen Biopharmaceutical for developing FG-M701 for inflammatory bowel disease (IBD).
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
JUNE 14, 2024
Following Roche, Merck and others into a hot field, the Humira maker will pay $150 million to license a preclinical TL1A antibody for IBD.
Pharmaceutical Technology
JUNE 14, 2024
England’s NHS has reported an 18% increase in the number of people with non-diabetic hyperglycaemia, also known as pre-diabetes.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
JUNE 14, 2024
India-based Suven Pharmaceuticals has announced a definitive agreement to acquire a strategic controlling stake in Sapala Organics.
Fierce Pharma
JUNE 14, 2024
With a deal worth up to $1.3 billion, Takeda could get its hands on a “potentially best-in-class” third-generation BCR-ABL tyrosine kinase inhibitor (TKI) that could rival Novartis' Scemblix.< | In deal potentially worth up to $1.3 billion, Takeda has gained an option to license Ascentage's third-generation tyrosine kinase inhibitor, which could go up against Novartis' Scemblix in chronic myeloid leukemia.
Pharmaceutical Technology
JUNE 14, 2024
Precision immunology company Santa Ana Bio has announced a substantial funding injection of $168m through Series A and B financing rounds.
Pharma Times
JUNE 14, 2024
The installation will double the capacity of cancer genomic testing using robotic automation
Pharmaceutical Technology
JUNE 14, 2024
After a successful trial, the UK NHS has become the first to permanently adopt a subscription payment model for new antibiotics.
pharmaphorum
JUNE 14, 2024
Stay up-to-date with the latest news in clinical trials with highlights from NMD Pharma, Minoryx Therapeutics, Moonlake Immunotherapeutics, and Ipsen. Discover the groundbreaking developments from 10th to 14th June.
Fierce Pharma
JUNE 14, 2024
Six months after Vertex earned a historic FDA approval for sickle cell d | Six months after Vertex earned a historic FDA approval for sickle cell disease (SCD) gene therapy Casgevy (exa-cel), long-term data is beginning to show the consistent efficacy and durability of the treatment, which is the first ever to be developed using CRISPR gene editing technology.
pharmaphorum
JUNE 14, 2024
Radiopharma firm Telix abandons Nasdaq listing plans Phil.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Fierce Pharma
JUNE 14, 2024
Each June, the American Society of Clinical Oncology (ASCO) hosts a conference that gathers physicians, researchers and the cancer community to share their latest research on treatments, technologi | In this week's episode of "The Top Line," journalists from Fierce Biotech and Fierce Pharma discuss the most talked-about data drops at ASCO and share on-the-ground details, including their experience with Gilead’s virtual reality Trodelvy ride.
pharmaphorum
JUNE 14, 2024
DeepWell gamifies breathing therapy for mental health Phil.
Fierce Pharma
JUNE 14, 2024
Despite some contract manufacturing growing pains in the post-COVID era, MilliporeSigma, the U.S. | MilliporeSigma is plugging €62 million (about $66.3 million) into the build-out of a new quality control building at its Darmstadt, Germany, headquarters. The facility will ultimately unite some 135 employees across several departments into a single space, the company said in a press release.
pharmaphorum
JUNE 14, 2024
FDA widens label for BMS’ cancer drug Augtyro Phil.
Drug Patent Watch
JUNE 14, 2024
This chart shows the drugs with the most patents in Bulgaria. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.
Fierce Pharma
JUNE 14, 2024
A Bristol Myers Squibb drug has got an FDA approval to treat tumors with a specific biomarker regardless of their locations in the body. | A Bristol Myers Squibb drug has got an FDA approval to treat tumors with a specific biomarker regardless of their locations in the body, and it's facing two competitors.
WCG Clinical
JUNE 14, 2024
Breaking Barriers: Reasons to Expand Site Cancer Clinical Trial Portfolios Download Breaking Barriers: Reasons to Expand Site Cancer Clinical Trial Portfolios Clinical trial research collaborations between physicians, hospital systems, and pharmaceutical companies are essential in advancing medical knowledge and improving patient care, particularly in cancer treatment.
Pharmaceutical Commerce
JUNE 14, 2024
The contract manufacturer financially committed over $107 million into the facility, which can reportedly handle large-scale manufacturing of active ingredients based on messenger ribonucleic acid.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
JUNE 14, 2024
Overcome Diverse Clinical Resistance Mechanisms with Emerging First- & Best-In-Class Combination & Monotherapies to Effectively Treat Patients with RA
Pharmaceutical Commerce
JUNE 14, 2024
In this Pharmaceutical Commerce video interview, Blake Powers, CEO of Medigi, discusses his first byline with the publication, along with why the industry may be stuck in its ways in certain aspects.
pharmaphorum
JUNE 14, 2024
Join the 3rd Operationalise: Early Access Programmes Summit Europe to gain insights and strategies for successful early access programs. Learn from industry experts and network with peers at this premier event.
XTalks
JUNE 14, 2024
Medication adherence is a critical factor in effective healthcare, with studies indicating that approximately 50% of patients do not follow their prescribed medication regimens. 1,2 This lack of adherence contributes significantly to poorer health outcomes and increased rates of hospital readmissions. The economic implications are profound, as nonadherence costs the US healthcare system an estimated $100 billion to $289 billion annually. 3 These costs stem from additional medical treatments, hos
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
JUNE 14, 2024
Discover the latest trends and developments in Real World Evidence (RWE) at the 12th IMPACCT Real World Evidence Summit. Explore how RWE is transforming drug development and healthcare outcomes.
Pharmaceutical Commerce
JUNE 14, 2024
The latest news for pharma industry insiders.
pharmaphorum
JUNE 14, 2024
Explore the latest trends and innovations in wearable injectors and connected devices at the Wearable Injectors and Connected Devices USA conference. Join industry leaders and experts for valuable insights and networking opportunities.
Advarra
JUNE 14, 2024
A regulatory binder is essential for managing clinical trial documents, ensuring regulatory compliance, and facilitating audits. It organizes critical documents; provides easy access for trial monitors, auditors, and regulatory authorities; and serves as a reference for the research team. Though not legally binding, maintaining a regulatory binder is highly recommended for all intervention trials.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
182 
Let's personalize your content